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Abstract 
Background: No predictor of postoperative ischemic events has been identified in patients 
undergoing carotid artery stenting. We aimed to determine whether N
ε
-(carboxymethyl)lysine 
in debris trapped by an embolic protection filter device is a predictor of postoperative 
ischemic events. Methods: We enrolled 27 patients (73.4 ± 7.2 years; 22 male, 5 female) 
who underwent carotid artery stenting for carotid artery stenosis. Diffusion-weighted 
magnetic resonance imaging was performed before and after the procedure. Protein samples 
were extracted from the debris. Nε-(carboxymethyl)lysine and myeloperoxidase were 
examined by solid phase enzyme-linked immunosorbent assay and western blot analysis. 
Results: Seventeen patients had zero or one new lesion (non-multiple lesions) 
postoperatively, whereas 10 patients had two or more new lesions postoperatively (multiple 
lesions). All three patients with transient neurological deficits after angioplasty showed 
multiple lesions. The Nε-(carboxymethyl)lysine concentration of the protein sample was 
significantly higher in patients with multiple lesions than in those with non-multiple lesions 
(6.26 ± 2.77 ng/mg protein and 3.36 ± 1.57 ng/mg protein, respectively; P = 0.010). Statin 
therapy for dyslipidemia was associated with a lower incidence of multiple lesions and a 
lower concentration of Nε-(carboxymethyl)lysine in the protein sample (P = 0.004 and P = 
0.02, respectively). Receiver operating characteristic analysis showed that the area under the 
curve for Nε-(carboxymethyl)lysine was significantly greater than 0.5 (0.877, 95% 
confidence interval: 0.742–1.00). Conclusions: Nε-(carboxymethyl)lysine derived from 
debris may distinguish between patients with postoperative multiple ischemic lesions and 
those with postoperative non-multiple lesions who undergo carotid artery stenting. 
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Introduction 
 Carotid artery stenting (CAS) is widely used to treat severe carotid artery stenosis. 
However, the benefits of CAS depend on the risk of procedural neurological complications. 
A main complication of CAS is an ipsilateral cerebral embolism of the treated artery. A new 
ischemic lesion detected on diffusion-weighted magnetic resonance imaging (DWI), a 
potential forerunner of cerebral embolism, was observed in 10–40% of patients who 
underwent CAS (1-3). The characteristics of the carotid plaque are one of the predisposing 
factors for new DWI ischemic lesions after CAS. Various circulating biomarkers associated 
with inflammation and oxidative stress such as myeloperoxidase (MPO) have been 
implicated in the instability and rupture of carotid atherosclerotic plaque (4). Imaging 
techniques, including magnetic resonance imaging (MRI) and ultrasound, have been used to 
evaluate the characteristics of carotid artery plaque. However, no biomarker has yet been 
identified for predicting new postoperative DWI ischemic lesions after CAS. 
 N
ε
-(carboxymethyl)lysine (CML) is one of the advanced glycation end products 
generated by a non-enzymatic reaction with glucose and protein. These are elevated in 
patients with diabetes mellitus and dyslipidemia, and they accumulate in atheroma and foam 
cells in association with plaque progression (5,6). Serum CML levels have been reported to 
increase in non-diabetic patients who suffer from coronary heart disease (7). Statin therapy 
has been associated with a decrease in CML levels and embolic particles in the filter device 
after CAS (8,9). However, CML can be derived from another pathway related to 
inflammation. MPO can be expressed in neutrophils and activating macrophages, and it 
plays a role in CML formation at the sites of inflammation (10). Moreover, the CML 
concentration is increased in human carotid rupture-prone plaques (11). These facts suggest 
that CML may be a predictor of new postoperative DWI ischemic lesions after CAS. 
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 The goals of the present study were 1) to identify CML and MPO in debris trapped 
by an embolic protection filter device during CAS; and (2) to determine whether these 
agents can predict postoperative ischemic events.  
Materials and Methods 
Study Subjects 
 We collected debris trapped by embolic protection filter devices in 27 consecutive 
patients (22 males, 5 females) who underwent CAS for severe carotid stenosis between 
August 2011 and February 2012 at Fukuoka University Chikushi Hospital. Patients who did 
not undergo MRI before CAS were excluded. The filter containing the debris (FilterWire 
EZ; Boston Scientific, Boston, MA, USA) was immediately washed with saline and stored 
at -40°C until use. Our study was approved by the research ethics committee of our 
institution (R11-033), and all patients gave informed consent. 
Clinical Data 
 Patients’ characteristics, including age, sex, symptomatic or asymptomatic status, 
hypertension (blood pressure, ≥140/90 mmHg measured on repeated occasions or use of 
hypotensive drugs), diabetes mellitus (HbA1c, >6.5%; fasting blood glucose, >126 mg/dl; 
or use of insulin or oral glucose inhibitors), dyslipidemia (fasting serum low density 
lipoprotein, ≥140 mg/dl; triglyceride, ≥150 mg/dl; high density lipoprotein, <40 mg/dl; or 
use of statin therapy), new postoperative DWI ischemic lesions, and neurological deficits 
were recorded after the procedure. New lesions were confirmed by DWI and an apparent 
diffusion coefficient map and were then counted. The images were analyzed by two 
neurosurgeons who were not among the main operators or attending surgeons for CAS. 
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Carotid Artery Stenting Procedures 
 All patients were treated with CAS according to the North American Symptomatic 
Carotid Endarterectomy Trial criteria. The operative indication for CAS was defined as 
symptomatic carotid artery stenosis ≥50% or asymptomatic carotid artery stenosis ≥80%. 
Symptomatic patients underwent CAS following medication for 4 weeks after a cerebral 
ischemic attack. All patients took antiplatelet agents (aspirin, 100 mg daily; clopidogrel 75 
mg daily; and cilostazol 200 mg daily) for at least 5 days preoperatively. 
 All CAS procedures were performed under general anesthesia. An 8-French sheath 
was introduced into the femoral artery, and heparin was injected into a vein until the 
activated clotting time exceeded 250 s (80 IU/kg). An 8-French guiding catheter was passed 
through the common carotid artery with the lesion, and after crossing the lesion, the 
FilterWire device was deployed distally into the internal carotid artery. Predilatation was 
performed with a 5–40 mm catheter balloon, and a 10–24 mm carotid stent was inserted in 
the internal to common carotid artery. Postdilatation was performed with a 7–20 mm 
catheter balloon. Antegrade blood flow was confirmed immediately by angiography. 
Magnetic Resonance Imaging 
 New ischemic brain lesions were identified by comparing the DWI images acquired 
before the CAS procedure to those within 1–3 days after the procedure. DWI was 
performed using the Signa HDxt 1.5T Optima Edition MRI system (GE Healthcare, 
Milwaukee, WI, USA) with the following parameters: b-value, 1,000 s/mm
2
; repetition 
time/echo time/excitation: 5,000 ms/81.5 ms/l; matrix, 128 × 128; field of view, 240 × 240 
mm; section thickness, 6 mm, interslice gap, 1.5 mm. 
Protein Extraction 
 The protein was extracted from the debris trapped by the FilterWire. Briefly, the 
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FilterWire was placed in a 200-µL lysis buffer (0.1% Triton X-100 in PBS) at 4°C, and 
sonication was performed three times using a Bioruptor UCD-200TM (Tosho Denki Co., 
Ltd., Kanagawa, Japan) at 4°C for 10 min. The supernatant was collected after 
centrifugation (15,000 rpm for 15 min at 4°C), and the protein concentration was measured 
using the Bradford method (Quick Start Bradford protein assay kit; Bio-Rad Lab Inc., 
Hercules, CA, USA) with bovine serum albumin as standard. 
Western Blot 
 Five microgram of each protein was applied to 10%-SDS PAGE, and 
immunoblotting was performed as previously described. Briefly, the protein was transferred 
to the nitrocellulose membrane and reacted with monoclonal anti-CML mouse antibody (1 
µg/mL, 6D12) (12) or polyclonal anti-MPO rabbit antibody (1:4,000 dilution; Millipore 
Corp., Bedford, MA, USA) at 4°C for 12 h. After washing, the membrane was incubated 
with horseradish peroxidase (HRP)-conjugated anti-mouse immunoglobulin (Ig)G (1:5,000 
dilution; Medical & Biological Laboratories Co., Ltd., Aichi, Japan) or anti-rabbit IgG 
(1:5,000 dilution; Medical & Biological Laboratories Co., Ltd.) for 1 h. The signals were 
exposed on radiography films after chemiluminescence with Western Lightning 
(PerkinElmer Co., Ltd., Boston, MA, USA). 
Solid Phase Enzyme-linked Immunosorbent Assay 
 The concentration of protein in each sample was adjusted to 2.5 µg/mL with 
carbonate-bicarbonate buffer, and each well of a 96-well microtiter plate was coated with 
100 µL of each sample at 4°C overnight. After blocking with 0.5% gelatin/PBS solution, 
each well was incubated with 6D12 (1 µg/mL, 100 µL/well) or polyclonal anti-MPO rabbit 
antibody (1:4,000 dilution; 100 µL/well) for 1 h and was then reacted with HRP-conjugated 
anti-mouse IgG (1:5,000 dilution, Medical & Biological Laboratories Co., Ltd.) or 
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anti-rabbit IgG (1:5000 dilution, Medical & Biological Laboratories Co., Ltd.) for 1 h. The 
absorbance was read at 492 nm with a micro-enzyme-linked immunosorbent assay plate 
reader following chemiluminescence with hydrogen peroxide or o-phenylenediamine. The 
CML and MPO concentrations in each sample were calculated using a standard curve 
provided by CML-BSA (STA-314; Cell Biolabs, Inc., San Diego, CA, USA) and MPO 
(ab91116; Abcam Ltd., Cambridge, UK). 
Statistical Analysis 
 Continuous variables were expressed as mean ± SD, and nominal variables were 
expressed as numerals and percentages. The Fisher’s probability exact test was used for 
comparisons of categorical data. Continuous variables were compared using Welch’s test. 
Relationships between two continuous variables were assessed using Pearson’s correlation 
analysis. A receiver operating characteristic (ROC) analysis was performed to determine 
whether CML and MPO can differentiate between patients with new multiple brain 
ischemic lesions and those with non-multiple brain ischemic lesions. Data analyses were 
performed using StatFlex, version 6.0 (Artech Co., Ltd., Osaka, Japan). A P-value <0.05 
was considered statistically significant. 
Results 
Patient Data and Clinical Results 
 The patients were classified into two groups: those with non-multiple lesions (zero 
or one new postoperative cerebral ischemic lesion; n = 17) and those with multiple lesions 
(n = 10). Table 1 shows the clinical characteristics of patients in both groups. No significant 
difference in mean age was observed. Patients with multiple lesions had a higher incidence 
of symptomatic onset than those with non-multiple lesions (P = 0.043). No difference in the 
incidence of hypertension, diabetes mellitus, and dyslipidemia was found between the 
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groups. Neurologic events developed within a few days in three patients who had multiple 
lesions, which were categorized as reversible ischemic neurologic deficits. 
Western Blot Analysis 
 Western blot analysis showed the presence of CML and MPO in the detergent 
extracts of the debris with protein bands of 63 kDa and 56/13 kDa, respectively (Figure 1). 
Both CML and MPO were detected in the debris of CAS samples 1 and 2, whereas the 
debris of CAS samples 4 and 5 showed an absence of CML and the presence of MPO, 
although the level of MPO was lower than that in CAS samples 1 and 2. The protein band of 
only CML was found in the debris of CAS sample 3. 
Solid Phase Enzyme-linked Immunosorbent Assay 
 Immunoassay using antibodies against CML and MPO indicated that CML-BSA and 
MPO were bound to the solid phase in a concentration-dependent manner (data not shown). 
CML levels in debris were significantly higher in patients with multiple lesions than in 
those with non-multiple lesions (6.26 ± 2.77 ng/mg protein vs. 3.36 ± 1.57 ng/mg protein, 
respectively; P < 0.01; Figure 2), whereas the MPO levels did not differ between the two 
groups (4.02 ± 2.17 ng/mg protein vs. 3.88 ± 3.80 ng/mg protein, respectively; P = not 
significant). 
The Effects of Statin Therapy 
 Only 16 of 22 patients with dyslipidemia underwent statin therapy. The incidence of 
multiple ischemic lesions after CAS was significantly lower in patients with dyslipidemia 
receiving statin therapy than in those not receiving such treatment (P = 0.004; Table 2). The 
CML levels in the debris were also significantly lower in the former than in the latter (3.20 
± 1.30 ng/mg protein vs. 5.65 ± 1.85 ng/mg protein, respectively; P = 0.02; Figure 3), 
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whereas the MPO levels did not differ between the groups. 
Correlation between N
ε
-(carboxymethyl)lysine and Myeloperoxidase in Debris 
 As shown in Figure 4, a significant correlation was observed between the CML and 
MPO levels in the debris (r = 0.44; P = 0.022). 
Receiver Operating Curve Analysis 
 Figure 5 shows the ROC analysis of CML and MPO for discriminating between 
patients with multiple lesions and those with non-multiple lesions. The ROC area under the 
curve (AUC) for CML was 0.877 (95% confidence interval [CI]: 0.742–1.00), whereas that 
for MPO was 0.627 (95% CI: 0.493–0.889). 
Discussion 
 The present study demonstrates for the first time that 1) the concentrations of CML 
in the debris trapped by an embolic protection filter device were significantly higher in 
patients with postoperative multiple ischemic lesions than in those with postoperative 
non-multiple lesions; 2) the CML concentrations helped distinguish the patients with 
postoperative multiple ischemic lesions from those with non-multiple lesions; and 3) statin 
therapy for dyslipidemia decreased the incidence of multiple ischemic lesions and the 
concentration of CML in the debris. 
 Soft and unstable plaques are prone to the generation of postoperative ischemic 
lesions after CAS (13,14). In addition, an ulcerated carotid stenosis or a plaque length of >1 
cm is an independent risk factor for new ipsilateral DWI lesions (15). An accumulation of 
CML, one of the major advanced glycation end products (AGEs), in an atherosclerotic 
lesion is associated with the progression of atheromatous plaque (10). Recently, CML levels 
were reported to increase in human rupture-prone carotid artery plaques and to mediate the 
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progression of stable to unstable plaques (11). Another report found no difference between 
the CML concentrations in the sera of symptomatic and asymptomatic patients with carotid 
artery stenosis (16). Semiquantitative analysis showed no significant difference between the 
AGEs in carotid plaque specimens from symptomatic and asymptomatic patients (16). In 
our study, the CML content was significantly higher in the debris from patients with 
multiple lesions than in the debris from those with non-multiple lesions. Additionally, ROC 
analysis for distinguishing between patients with multiple lesions and those with 
non-multiple lesions showed that the AUC for CML was significantly >0.5 (0.877, 95% CI: 
0.742–1.00). Thus, CML in the debris distinguished between the patients who developed 
multiple cerebral ischemic lesions after CAS and those with non-multiple cerebral ischemic 
lesions. 
 According to DWI, CAS has been shown to cause cerebral micro-embolization in 
approximately half of all cases. Protected patients revealed a significantly lower incidence 
of postoperative ischemic lesions after CAS than in unprotected patients (2,17). Patients 
who developed a stroke after CAS showed more new DWI lesions than those who did not 
develop a stroke after CAS (2). However, the procedures during CAS may cause cerebral 
micro-embolization. For instance, the cleavage of plaque by the balloon vasodilatation 
during CAS can induce multiple atheromatous embolisms (18). In our study, postoperative 
multiple ischemic lesions were found in all three patients who had postoperative 
neurological deficits. The proportion of symptomatic patients was greater among those with 
multiple lesions than in those with non-multiple lesions. Finally, the CML debris content in 
patients with multiple lesions was higher than in those with non-multiple lesions and was 
positively correlated with the MPO content that was found in unstable carotid plaque. These 
findings suggest that multiple cerebral ischemic lesions may be induced by 
micro-embolization during and after CAS in patients with unstable carotid plaque. 
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 AGEs can be derived from several pathways. Previous reports have demonstrated 
that glycated and/or oxidized low-density lipoprotein (LDL) accumulated in arterial intima 
contributes to the development of atherosclerosis (19,20). MPO is formed by neutrophils 
and activating macrophages, and contributes to the progression and destabilization of the 
plaque (21,22). Recently, MPO produced by neutrophils and activating macrophages has 
been shown to generate CML-modified proteins (23). Glycolaldehyde-pyridine, an 
MPO-derived advanced end product, is shown to accumulate in human atherosclerotic 
plaque (24). In this study, the concentration of CML in debris was positively correlated with 
that of MPO. Therefore, CML may be formed, not only by glycoxidation of LDL but also 
by MPO derived from inflammatory cells such as neutrophils and macrophages. 
 Recent studies showed the pleiotropic effects of statin therapy, including attenuation 
of vascular inflammation, improved endothelial cell function, and stabilization of plaque 
(25,26). It has been suggested that statin therapy may prevent receptor (R)AGE-mediated 
atherogenesis by reducing serum AGEs and increasing the soluble RAGE (27). Statin 
therapy is associated with smaller quantities of embolic particles in the filter device after 
CAS (9). The randomized ARMYDA-9 CAROTID study demonstrated that preoperative 
statin therapy significantly reduced the transient ischemic attack or stroke rate at 30 days 
and the generation of postoperative cerebral ischemic lesions after CAS (28). Our study 
showed that statin therapy was associated with a decreased incidence of multiple lesions 
after CAS. The CML content in the debris of patients receiving statin therapy was 
significantly lower than in those without statin therapy. These results suggest that statin 
therapy can prevent the generation of multiple cerebral ischemic lesions after CAS, as a 
result of the decreased CML formation. 
 This study has some limitations. Firstly, because of the small number of patients (27 
cases), we cannot determine whether CML may be used to distinguish between patients 
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with multiple postoperative ischemic events and those with non-multiple ischemic events 
independent from other factors, such as diabetes mellitus, dyslipidemia, or soft and unstable 
carotid plaques. Secondly, we measured the CML content in debris trapped by the filter 
device. The quantity and quality of the trapped debris are dependent on the embolic 
protection device and the CAS procedure. Data on the serum levels of CML may be more 
useful for predicting postoperative ischemic events in patients with carotid artery stenosis.  
Conclusions 
 CML derived from debris may help distinguish between patients with multiple 
postoperative ischemic events and those with non-multiple ischemic events who undergo 
CAS. However, the precise role and predictive value of CML needs to be confirmed by 
larger studies that include data on the serum CML levels. 
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Figure Legends 
Figure 1. Western blot analysis of N
ε
-(carboxymethyl)lysine (CML)-modified protein and 
myeloperoxidase (MPO) in the debris. 
The protein samples of debris are subjected to SDS-PAGE and western blot analysis using 
the 6D12 antibody and anti-MPO antibody. Panel A indicates CML-modified protein, which 
is expressed at about 63 kDa. Panel B indicates two bands of MPO (59 kDa and 13.5 kDa 
molecular weight molecules). The CML-modified protein and MPO are detected in CAS 
samples 1 and 2. In contrast, CAS samples 4 and 5 show the absence of CML-modified 
protein and the presence of MPO, though less than in samples 1 and 2. Only CML-modified 
protein is detected in sample 3. 
Figure 2. Comparison of N
ε
-(carboxymethyl)lysine (CML) and myeloperoxidase (MPO) 
contents in the debris of patients with multiple and non-multiple lesions. 
The CML and MPO were measured by solid phase enzyme-linked immunosorbent assay with 
the monoclonal anti-CML antibody (6D12) and polyclonal anti-MPO antibody, respectively. 
Data are expressed as mean ± standard deviation. The CML content was significantly higher 
in patients with multiple lesions (6.26 ± 2.77 ng/mg protein, n = 10) than in those with 
non-multiple lesions (3.36 ± 1.57 ng/mg protein, n = 17). In contrast, the MPO content did 
not differ between patients with multiple and non-multiple lesions (4.02 ± 2.17 ng/mg protein 
vs. 3.88 ± 3.80 ng/mg protein, respectively). The differences were tested using Welch’s test. 
*P = 0.010. 
Figure 3. The effect of statin therapy on N
ε
-(carboxymethyl)lysine (CML) and 
myeloperoxidase (MPO) contents in the debris among patients with dyslipidemia. 
The CML and MPO were measured by solid phase enzyme-linked immunosorbent assay with 
the monoclonal anti-CML antibody (6D12) and polyclonal anti-MPO antibody, respectively.  
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Data are expressed as mean ± standard deviation. The CML content was significantly lower 
in patients with statin therapy (3.20 ± 1.30 ng/mg protein, n = 16) than in those without (5.65 
± 1.85 ng/mg protein, n = 6). In contrast, no difference was found in the MPO content for 
those with and without statin therapy (3.25 ± 3.51 ng/mg protein vs. 4.54 ± 3.02 ng/mg 
protein, respectively). The differences were tested using Welch’s test. *P = 0.02. 
Figure 4. Linear regression analysis of the relationship between N
ε
-(carboxymethyl)lysine 
(CML) and myeloperoxidase (MPO) in the debris. 
The contents of CML and MPO were measured by solid phase enzyme-linked 
immunosorbent assay with the monoclonal anti-CML antibody (6D12) and anti-MPO 
antibody, respectively. The CML content was positively correlated with the MPO content. 
Linear regression analysis was performed using Pearson’s correlation analysis (correlation 
coefficient: 0.44; P = 0.022). 
Figure 5. Comparison of N
ε
-(carboxymethyl)lysine (CML) and myeloperoxidase (MPO) in 
the debris according to the receiver operative curve (ROC) analysis. 
The contents of CML and MPO were measured by solid phase enzyme-linked 
immunosorbent assay with the monoclonal anti-CML antibody (6D12) and anti-MPO 
antibody, respectively. The ROC curves of CML and MPO were generated to distinguish 
between the patients with multiple lesions and those with non-multiple lesions. The area 
under the curves for CML and MPO were 0.877 (95% confidence interval [CI], 0.742–
1.000) and 0.627 (95% CI, 0.493–0.889), respectively. 
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Table 1. Clinical characteristics of patients according to diffusion weight imaging. 
 New DWI lesion after CAS  
 
Non-multiple 
lesion 
Multiple lesions P 
No. of patients (n = 27) 17 10 
 
  
  
  
Mean age 72.6 ± 6.7 74.8 ± 8.1 0.46 
  
  
  
Sex 
  
  
Male (n = 22) 12 (54.5%) 10 (45.5%) 0.08 
Female (n = 5) 5 (100%) 0 (0%)   
  
  
  
Onset 
  
  
Asymptomatic (n = 20) 15 (75%) 5 (25%) 0.043 
Symptomatic (n = 7) 2 (28.6%) 5 (71.4%)   
  
  
  
   
  
Hypertension    
No (n = 7) 6 (85.7%) 1 (14.3%) 0.16 
Yes (n = 20) 11 (55%) 9 (45%)  
    
Diabetes mellitus    
No (n = 18) 11 (61.1%) 7 (38.9%) 0.56 
Yes (n = 9) 6 (66.7%) 3 (33.3%)  
    
Dyslipidemia    
No (n = 5) 2 (40%) 3 (60%) 0.25 
Yes (n = 22) 15 (68.2%) 7 (31.8%)  
  
  
  
Neurological deficits 
after CAS    
No (n = 24) 17 (70.8%) 7 (29.2%) 0.041 
Yes (n = 3) 0 (0%) 3 (100%) 
 
Data are mean values ± standard deviation or n (%). Statistical analyses were performed using Welch’s test and Fisher’s 
probability exact test. 
Non-multiple lesion: No lesion or single lesion. 
Multiple lesions: Two or more new lesions 
DWI: diffusion weight imaging; CAS: carotid artery stenting.
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Table 2. The effect of statin therapy on new diffusion weight imaging lesions 
among patients with dyslipidemia. 
 New DWI lesion after CAS  
 
Non-multiple lesion Multiple lesions P 
Statin therapy    
No (n = 6) 1 (16.7%) 5 (83.3%) 0.004 
Yes (n = 16) 14 (87.5%) 2 (12.5%)  
Data are n (%). Statistical analyses were performed using Fisher’s probability exact. 
Non-multiple lesion: No lesion or single lesion. 
Multiple lesions: Two or more new lesions 
DWI: diffusion weight imaging; CAS: carotid artery stenting.
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